EBS
Emergent BioSolutions Inc.
Key Financials
Operating Income
$100.1M
↑ 192.1%
Revenue
$742.9M
↓ 28.8%
EPS (Diluted)
$0.93
↑ 125.8%
Net Income
$52.6M
↑ 127.6%
Total Assets
$1.3B
↓ 5.1%
Cash & Equivalents
$205.4M
↑ 106.4%
Shareholders' Equity
$522.6M
↑ 8.2%
Long-term Debt
$589.7M
↓ 15.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G | 8/14/2026 | View on SEC |
| 3 | 8/12/2026 | View on SEC |
| 10-Q | 8/6/2026 | View on SEC |
| 8-K | 8/5/2026 | View on SEC |
| SCHEDULE 13G/A | 7/31/2026 | View on SEC |
| SCHEDULE 13G/A | 7/28/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 144 | 7/1/2026 | View on SEC |
| 8-K | 6/29/2026 | View on SEC |
| 4 | 6/10/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | EBS |
| Company Name | Emergent BioSolutions Inc. |
| CIK | 1367644 |
| Sector | Pharmaceutical Preparations |
| Industry | Accelerated filer |
| Exchange | NYSE |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 240-631-3200 |